DURECT Corporation (DC8.SG)
| Previous close | 0.0000 |
| Open | 0.3600 |
| Bid | 0.3540 x 500000 |
| Ask | 0.3860 x 500000 |
| Day's range | 0.0000 - 0.3600 |
| 52-week range | |
| Volume | |
| Avg. volume | 11,100 |
| Market cap | 0 |
| Beta (5Y monthly) | 0.88 |
| PE ratio (TTM) | -0.00 |
| EPS (TTM) | -0.1540 |
| Earnings date | 06 May 2024 - 10 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
PR NewswireDURECT Corporation Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
DURECT Corporation (Nasdaq: DRRX) today announced financial results for the fourth quarter and year ended December 31, 2023 and provided a business update.
- PR Newswire
DURECT Corporation to Announce Fourth Quarter and Full Year 2023 Financial Results and Provide a Business Update
DURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the treatment of serious and life-threatening conditions, including acute organ injury and cancer, today announced that the company will report its fourth quarter and full year 2023 financial results on Wednesday, March 27, 2024. Management will also host a conference call and webcast with investors to discuss financial results and provide a corporate update a
- PR Newswire
DURECT and Charles River Laboratories Enter into Co-Marketing and Collaboration Agreement for ALZET® Product Line in U.S. and Canada
DURECT Corporation (Nasdaq: DRRX), today announced that it has entered into a co-marketing and collaboration agreement with Charles River Laboratories for the ALZET® Osmotic Pumps Portfolio and Associated Product Line in the U.S. and Canada. Charles River is a highly respected, global provider of drug discovery and non-clinical development solutions.
